Imatinib Dose Can Be Safely Reduced after Complete Cytogenetic Response (CCyR) in Patients (pts) with Chronic Myeloid Leukemia (CML) in Early Chronic Phase (CP) Treated with High-Dose Imatinib.
Abstract
Data di Pubblicazione:
2007
Tipologia CRIS:
04E-Meeting abstract in rivista
Elenco autori:
Nitin Jain; Hagop M. Kantarjian; Carmen Fava; Deborah Thomas; Jan A. Burger; Gautam Borthakur; Odeal Pate; and Jorge Cortes.
Link alla scheda completa:
Pubblicato in: